Page last updated: 2024-08-22

molybdenum and Lassitude

molybdenum has been researched along with Lassitude in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Antonarakis, ES; Beer, TM; Callahan, JA; Carducci, MA; Gordon, G; Lin, J; Mathew, P; Morris, M; Reich, SD; Ryan, CJ; Wilding, G; Zahurak, M	1

Trials

1 trial(s) available for molybdenum and Lassitude

Article	Year
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. Urologic oncology, 2013, Volume: 31, Issue:5 Topics: Aged; Aged, 80 and over; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fatigue; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Molybdenum; Nausea; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Superoxide Dismutase; Time Factors; Treatment Outcome	2013

Article

Year

A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.

Urologic oncology, 2013, Volume: 31, Issue:5

Topics: Aged; Aged, 80 and over; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fatigue; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Molybdenum; Nausea; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Superoxide Dismutase; Time Factors; Treatment Outcome

2013